Target for therapy of cognitive impairment

A pharmaceutical composition comprising a therapeutically effective amount of:

• wherein, individually for each occurrence:
• L is O or S;
• R is H, C1-10 alkyl, C1-10 alkoxy, aryl, aralkyl, —OCH2CO2H;
• R1 is —(CH2)n—C(O)X
• wherein
• X is OH, NR2, SH, O-alkali metal, or —OC(CH3)OC(O)OCH(CH3)2;
• and
• n is an integer from 0 to 6 inclusive;
• R2 is H, C1-10 alkyl, C2-8 alkenyl, or —(CH2)a—W—R3
• wherein
• R3 is H, C1-10 alkyl, —C(O)C1-10 alkyl, —C(O)NR2) aryl, aralkyl, or A;
• W is O, S, or NR4;
• and
• a is an integer from 1 to 6 inclusive;
• wherein
• R4 is H, C1-10 alkyl, —C(O)C1-10 alkyl, aryl, aralkyl, or R3 and R4 taken together may form an unsubstituted or substituted heteroalkyl or heteroaryl ring;
• the line indicates either a single or double bond;
• R5 is R1, H, SO3H, aryl, C1-10 alkyl, aralkyl;
• or R5 is selected from the group consisting of ═CHCH2CO2H and ═NR when the line is a double bond;
• m is 0 or 1;
• and
• A is aryl or heteroaryl of formula Ia:
• wherein, independently for each occurrence:
• J is O, S, NR6, or CR6;
• and
• y is 1 or 2;
• wherein R6 is an electron pair, H, 1-10 alkyl, C1-10 alkoxy, aryl, or —NR2;
• or
• A is heterocycloalkyl of formula Ib or Ic:
• herein, independently for each occurrence:
• J is O, S, or NR;
• and
• X is O or H2.